BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24330666)

  • 1. An International Collaborative Study to establish the WHO 2nd International Standard for High Molecular Weight Urokinase: communication from SSC of the ISTH.
    Longstaff C; Thelwell C; Rigsby P;
    J Thromb Haemost; 2014; 12(3):415-7. PubMed ID: 24330666
    [No Abstract]   [Full Text] [Related]  

  • 2. An international collaborative study to calibrate the WHO 2nd International Standard for Ancrod (15/106) and the WHO Reference Reagent for Batroxobin (15/140): communication from the SSC of the ISTH.
    Thelwell C; Rigsby P; Locke M; Bevan S; Longstaff C
    J Thromb Haemost; 2018 May; 16(5):1003-1006. PubMed ID: 29607604
    [No Abstract]   [Full Text] [Related]  

  • 3. An International Collaborative Study to establish the World Health Organization 4th International Standard for Plasmin (13/206): communication from the SSC of the ISTH.
    Thelwell C; Longstaff C; Rigsby P;
    J Thromb Haemost; 2016 Jan; 14(1):215-8. PubMed ID: 27028402
    [No Abstract]   [Full Text] [Related]  

  • 4. [Inactivation and stabilization of urokinase fibrinolytic activity in vitro].
    Aĭsina RB; Mukhametova LI; Sazonova IIu; Varfolomeev SD
    Bioorg Khim; 1998 Jul; 24(7):544-8. PubMed ID: 9749317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An international collaborative study to establish the World Health Organization 2nd International Standard for Factor VII Concentrate: communication from the SSC of the ISTH.
    Thelwell C; Rigsby P; Bevan S; Beeharry M;
    J Thromb Haemost; 2014 Oct; 12(10):1750-3. PubMed ID: 25056848
    [No Abstract]   [Full Text] [Related]  

  • 6. [High Molecular Weight Urokinase Reference Standard (Control 901) of National Institute of Health Sciences].
    Okada S; Yomota C; Murai M; Tanimoto T; Kimura T
    Eisei Shikenjo Hokoku; 1993; (111):133-6. PubMed ID: 7920555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International collaborative study on the assay of commerically available high and low molecular weight urokinases.
    Gaffney PJ; Tydeman MS; Kirkwood TB; Aronson D; Murano G
    Thromb Haemost; 1981 Feb; 45(1):34-7. PubMed ID: 7018003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A collaborative study to establish a standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA).
    Gaffney PJ; Heath AB
    Thromb Haemost; 1990 Nov; 64(3):398-401. PubMed ID: 2128969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International collaborative study to establish the World Health Organization 2nd International Standard for Fibrinogen Concentrate (09/242): communication from the SSC of the ISTH.
    Raut S; Hamill M; Heath AB;
    J Thromb Haemost; 2016 Oct; 14(10):2068-2072. PubMed ID: 27660008
    [No Abstract]   [Full Text] [Related]  

  • 10. Calibration of the WHO 1st international standard and SSC/ISTH secondary coagulation standard for tissue plasminogen activator antigen in plasma.
    Longstaff C; Rigsby P; Whitton C;
    J Thromb Haemost; 2010 Aug; 8(8):1855-7. PubMed ID: 20546122
    [No Abstract]   [Full Text] [Related]  

  • 11. Amediplase. Menarini.
    Doggrell SA
    Curr Opin Investig Drugs; 2004 Mar; 5(3):344-7. PubMed ID: 15083603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification of high molecular weight urokinase from human urine and comparative study of two active forms of urokinase.
    Shibatani T; Kakimoto T; Chibata I
    Thromb Haemost; 1983 Apr; 49(2):91-5. PubMed ID: 6346574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Isolation of a third human urokinase (S0 type)].
    Doleschel W
    Wien Klin Wochenschr; 1975 Apr; 87(8):282-4. PubMed ID: 1220276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimentally targeted thrombolytic therapy. Application of modified thrombin conjugated with urokinase.
    Maksimenko AV; Petrov AD; Tischenko EG; Smirnov MD
    Ann N Y Acad Sci; 1995 Mar; 750():496-501. PubMed ID: 7785879
    [No Abstract]   [Full Text] [Related]  

  • 15. Physicochemical properties of highly purified kidney cultured plasminogen activator (single chain urokinase).
    Sumi H; Kosugi T; Matsuo O; Mihara H
    Nihon Ketsueki Gakkai Zasshi; 1982 Feb; 45(1):119-28. PubMed ID: 7051725
    [No Abstract]   [Full Text] [Related]  

  • 16. Establishment of replacement batches for heparin low-molecular-mass for calibration CRS, and the International Standard Low Molecular Weight Heparin for Calibration.
    Mulloy B; Heath A; Behr-Gross ME
    Pharmeuropa Bio; 2007 Dec; 2007(1):29-48. PubMed ID: 18413136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolytic agents.
    Collen D; Lijnen HR
    Thromb Haemost; 2005 Apr; 93(4):627-30. PubMed ID: 15841305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of the high effective thrombolytic agents with molecular biological technique].
    Wu HZ; Li JZ
    Zhonghua Nei Ke Za Zhi; 1993 Jan; 32(1):11-3. PubMed ID: 8404311
    [No Abstract]   [Full Text] [Related]  

  • 19. Urokinase activity after freezing: implications for thrombolysis in intraventricular hemorrhage.
    Rhoney DH; Coplin WM; Zaran FK; Brish LK; Weingarten CM
    Am J Health Syst Pharm; 1999 Oct; 56(20):2047-51. PubMed ID: 10541031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ideal fibrinolytic: can drug design improve clinical results?
    Van de Werf FJ
    Eur Heart J; 1999 Oct; 20(20):1452-8. PubMed ID: 10493843
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.